About: Architectural Insight into Inovirus-Associated Vectors (IAVs) and Development of IAV-Based Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Architectural Insight into Inovirus-Associated Vectors (IAVs) and Development of IAV-Based Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Architectural Insight into Inovirus-Associated Vectors (IAVs) and Development of IAV-Based Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines
Creator	Hassapis, Kyriakos Kostrikis, Leondios Stylianou, Dora
Source	Medline; PMC
abstract	Inovirus-associated vectors (IAVs) are engineered, non-lytic, filamentous bacteriophages that are assembled primarily from thousands of copies of the major coat protein gp8 and just five copies of each of the four minor coat proteins gp3, gp6, gp7 and gp9. Inovirus display studies have shown that the architecture of inoviruses makes all coat proteins of the inoviral particle accessible to the outside. This particular feature of IAVs allows foreign antigenic peptides to be displayed on the outer surface of the virion fused to its coat proteins and for more than two decades has been exploited in many applications including antibody or peptide display libraries, drug design, and vaccine development against infectious and non-infectious diseases. As vaccine carriers, IAVs have been shown to elicit both a cellular and humoral response against various pathogens through the display of antibody epitopes on their coat proteins. Despite their high immunogenicity, the goal of developing an effective vaccine against HIV-1 has not yet materialized. One possible limitation of previous efforts was the use of broadly neutralizing antibodies, which exhibited autoreactivity properties. In the past five years, however, new, more potent broadly neutralizing antibodies that do not exhibit autoreactivity properties have been isolated from HIV-1 infected individuals, suggesting that vaccination strategies aimed at producing such broadly neutralizing antibodies may confer protection against infection. The utilization of these new, broadly neutralizing antibodies in combination with the architectural traits of IAVs have driven the current developments in the design of an inovirus-based vaccine against HIV-1. This article reviews the applications of IAVs in vaccine development, with particular emphasis on the design of inoviral-based vaccines against HIV-1.
has issue date	2014-12-17(xsd:dateTime)
bibo:doi	10.3390/v6125047
bibo:pmid	25525909
has license	cc-by
sha1sum (hex)	f6e6534cb423c1823ad38d7d5c0a98c303f2efdb
schema:url	https://doi.org/10.3390/v6125047
resource representing a document's title	Architectural Insight into Inovirus-Associated Vectors (IAVs) and Development of IAV-Based Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines
has PubMed Central identifier	PMC4276942
has PubMed identifier	25525909
schema:publication	Viruses
resource representing a document's body	covid:f6e6534cb423c1823ad38d7d5c0a98c303f2efdb#body_text
is schema:about of	named entity 'potent' named entity 'drug design' named entity 'producing' named entity 'VACCINES' named entity 'GP8' named entity 'BACTERIOPHAGES' named entity 'EPITOPES' named entity 'HUMORAL RESPONSE' named entity 'PREVIOUS' named entity 'TRAITS' named entity 'ELICIT' named entity 'COAT PROTEIN' named entity 'IN THE PAST' named entity 'VIRION' named entity 'DISPLAY' named entity 'ARCHITECTURE' named entity 'CURRENT' named entity 'THEIR' named entity 'EXHIBIT' named entity 'PROTECTION' named entity 'VACCINE' named entity 'ALLOWS' named entity 'MORE THAN' named entity 'PEPTIDES' named entity 'MINOR' named entity 'GP6' named entity 'CARRIERS' named entity 'HIV-1' named entity 'BASED' named entity 'INOVIRUS' named entity 'GP9' named entity 'ITS' named entity 'STRATEGIES' named entity 'DEVELOPMENTS' named entity 'ACCESSIBLE' named entity 'INFECTIOUS' named entity 'APPLICATIONS' named entity 'PRODUCING' named entity 'FUSED TO' named entity 'CELLULAR' named entity 'INSIGHT' named entity 'ASSOCIATED' named entity 'DEVELOPMENT' named entity 'VECTORS' named entity 'NON-' named entity 'HIV-1' named entity 'JUST' named entity 'SURFACE' named entity 'BASED' named entity 'ENGINEERED' named entity 'NEW' named entity 'COPIES' named entity 'YEARS' named entity 'FOREIGN' named entity 'DO NOT' named entity 'FILAMENTOUS' named entity 'INDIVIDUALS' named entity 'HAVE' named entity 'DEVELOPING' named entity 'INFECTIOUS DISEASES' named entity 'DESIGN' named entity 'PEPTIDE' named entity 'THOUSANDS' named entity 'BROADLY NEUTRALIZING ANTIBODIES' named entity 'LIMITATION' named entity 'OUTER' named entity 'IMMUNOGENICITY' named entity 'THESE' named entity 'GOAL' named entity 'POSSIBLE' named entity 'DRIVEN' named entity 'VECTORS' named entity 'OUTSIDE' named entity 'PARTICLE' named entity 'INFECTION' named entity 'CELLULAR' named entity 'PARTICULAR' named entity 'INCLUDING' named entity 'VACCINE DEVELOPMENT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software